Selumetinib
Selumetinib
Selumetinib (pronounced se-loo-MET-in-ib) is a medication used in the treatment of certain types of cancer. It is a type of kinase inhibitor, specifically a MEK inhibitor, which works by blocking the action of a certain protein in the body that helps cancer cells multiply.
Etymology
The name "Selumetinib" is derived from the compound's chemical structure. "Selu" is a prefix used in pharmaceutical nomenclature to denote selective inhibitors, "met" refers to the drug's action on the MEK protein, and "inib" is a common suffix for kinase inhibitors.
Usage
Selumetinib is used to treat neurofibromatosis type 1 (NF1) in pediatric patients who have symptomatic, inoperable plexiform neurofibromas (PN). It is also being studied in the treatment of other types of cancer.
Related Terms
- Kinase inhibitor: A type of drug that blocks certain proteins called kinases.
- MEK inhibitor: A type of kinase inhibitor that blocks the action of a protein called MEK.
- Neurofibromatosis type 1 (NF1): A genetic disorder characterized by the growth of non-cancerous tumors along nerves in the skin, brain, and other parts of the body.
- Plexiform neurofibromas (PN): A type of tumor that occurs in people with NF1.
Side Effects
Common side effects of Selumetinib include nausea, vomiting, diarrhea, rash, and fatigue. More serious side effects can include heart problems, eye problems, and lung or breathing problems.
See Also
External links
- Medical encyclopedia article on Selumetinib
- Wikipedia's article - Selumetinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski